Eli Lilly is seeking to intervene in a lawsuit filed by compounding pharmacies against the FDA regarding the supply status of its weight-loss drug Zepbound and diabetes drug Mounjaro, both containing tirzepatide. Lilly claims it cannot depend solely on the FDA for its defense, as the case could determine the legality of selling cheaper compounded versions of its drugs. The FDA recently affirmed that there is no shortage of these medications, which affects compounded production approvals. Meanwhile, Lilly has been taking legal action against telehealth companies selling unapproved versions of its drugs, securing its interests amid ongoing market competition.